Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN®) and ChAdOx1 nCoV-19 (COVISHIELD™) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational study.
Asokan MS, Joan RF, Babji S, Dayma G, Nadukkandy P, Subrahmanyam V, Pandey A, Malagi G, Arya P, Mahajan V, Bhavikatti J, Pawar K, Thorat A, Shah P, Goud RB, Roy B, Rajukutty S, Immanuel S, Agarwal D, Saha S, Shivaraj A, Panikulam P, Shome R, Gulzar SE, Sharma AU, Naik A, Talashi S, Belekar M, Yadav R, Khude P, V M, Shivalingaiah S, Deshmukh U, Bhise C, Joshi M, Inbaraj LR, Chandrasingh S, Ghose A, Jamora C, Karumbati AS, Sundaramurthy V, Johnson A, Ramesh N, Chetan N, Parthiban C, Ahmed A, Rakshit S, Adiga V, D'souza G, Rale V, George CE, John J, Kawade A, Chaturvedi A, Raghunathan A, Dias M, Bhosale A, Raghu P, Shashidhara LS, Vyakarnam A, Bal V, Kang G, Mayor S.
Asokan MS, et al. Among authors: jamora c.
Lancet Reg Health Southeast Asia. 2024 Feb 27;22:100361. doi: 10.1016/j.lansea.2024.100361. eCollection 2024 Mar.
Lancet Reg Health Southeast Asia. 2024.
PMID: 38482152
Free PMC article.